SYRE SPYRE THERAPEUTICS INC.

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.

To access the live and archived webcast, please visit the Investor Relations page of Spyre’s website at .

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at .

For Investors:

Eric McIntyre, Spyre Therapeutics

SVP of Finance and Investor Relations

For Media:

Josie Butler, 1AB



EN
10/04/2026

Underlying

SYRESPYRE THERAPEUTICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SPYRE THERAPEUTICS INC.

 PRESS RELEASE
Free
SYRE SPYRE THERAPEUT...

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Ind...

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcer...

April 10, 2026 1 EN
 PRESS RELEASE
Free
SYRE SPYRE THERAPEUT...

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equi...

April 3, 2026 1 EN
 PRESS RELEASE
Free
SYRE SPYRE THERAPEUT...

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rhe...

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of SKYWAY remain on track; Week 16 topline readouts expected in Q4 2026 SKYLINE platform trial in ulcerative colitis (UC) continues to enroll ahead of schedule; Part A readouts to begin in Q2 2026 WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- ...

March 16, 2026 1 EN
 PRESS RELEASE
Free
SYRE SPYRE THERAPEUT...

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 46,600 shares of common stock of Spyre to two non-executive employees as equit...

March 6, 2026 1 EN
 PRESS RELEASE
Free
SYRE SPYRE THERAPEUT...

Spyre Therapeutics to Participate in Upcoming March Investor Conferenc...

Spyre Therapeutics to Participate in Upcoming March Investor Conferences WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: TD Cowen 46th Annual Health Care Conference - BostonDate: Tuesday, March 3, 2026Presentation and Fireside Time: 3:10 pm ET Event: ...

February 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch